Welcome to our dedicated page for Corteva SEC filings (Ticker: CTVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Corteva, Inc. filings document the reporting obligations of a NYSE-listed agriculture company with common stock registered under the Exchange Act. Form 8-K reports cover quarterly and annual operating results, furnished earnings releases, financial statement schedules, annual meeting voting results, executive officer changes, board matters, dividend-related disclosures, and strategic separation planning for its agriculture businesses.
The company's definitive proxy materials provide governance and compensation disclosures, including director elections, shareholder proposals, executive compensation tables, equity awards, board oversight, and stockholder voting matters. Corteva's filing record also identifies its capital structure, including common stock and preferred stock matters involving EIDP, Inc., a wholly owned subsidiary.
Capital World Investors, a division of Capital Research and Management Company and its investment management affiliates, reports beneficial ownership of 43,841,218 shares of Corteva, Inc. common stock. This represents 6.6% of the 667,018,000 shares Corteva believes are outstanding as of June 30, 2026. Capital World Investors has sole voting power over 43,417,923 shares and sole dispositive power over 43,841,218 shares, with no shared voting or dispositive power reported. The filing reflects the holdings of multiple affiliated investment management entities that collectively provide services under the Capital World Investors name.
On July 31, 2026, Corteva, Inc. director Christopher J. Policinski acquired 412.9081 stock units tied to common stock under the Stock Accumulation and Deferred Compensation Plan for Directors, using a reference price of $78.7100 per share based on deferred cash fees.
Following this award, his directly held stock units increased to 2768.4952, including 5.5871 shares added through dividend reinvestment.
Corteva, Inc. director Nayyar Nayaki R reported an acquisition of 412.9081 stock units tied to common stock on July 31, 2026. The units were credited under a Stock Accumulation and Deferred Compensation Plan, using the $78.71 closing price. A footnote states his reported direct holdings now include 86.1950 shares from dividend reinvestment, for a total of 36,753.6815 common stock equivalents.
Corteva, Inc. director Janet Plaut Giesselman acquired 98.4627 stock units of common stock on July 31, 2026 at $78.71 per unit through the Stock Accumulation and Deferred Compensation Plan for Directors. Her direct holdings rose to 20,247.7383 stock units, including 46.7056 shares from dividend reinvestment. The acquisition was not reported as made under a Rule 10b5-1 trading plan.
Corteva reported Q2 2026 net sales of $6,379 million (vs $6,456 million a year earlier) and net income attributable to Corteva of $1,161 million (vs $1,314 million), or diluted EPS of $1.73. For the first six months, net sales were $11,284 million and net income attributable to Corteva was $1,881 million.
Seed generated $7,555 million of year‑to‑date sales, led by North America corn and soybeans, while Crop Protection contributed $3,729 million. Operating cash flow for the first half was negative $3,357 million, reflecting large deferred‑revenue run‑off, working‑capital swings and pension contributions of $1,140 million. Cash and restricted cash totaled $2,619 million, with short‑term borrowings of $3,193 million and $6,000 million of committed credit facilities.
Management approved 2026 restructuring actions (~$80 million of severance) and continues the multi‑year Crop Protection Operations Strategy, expected to incur $750–$815 million of pre‑tax charges through 2028 (of which $674 million is recorded). Corteva also recorded sizable legal and environmental items, including a $610 million settlement with Bayer, PFAS‑related cost‑sharing under a memorandum of understanding, and settlements of Federal Trade Commission and related antitrust lawsuits, contributing to current accrued litigation of $468 million alongside significant indemnification assets.
Corteva, Inc. reported second-quarter and first-half 2026 results and updated its 2026 outlook. For Q2 2026, net sales were $6,379 million, down 1% year over year, while non-GAAP Operating EBITDA rose 4% to $2.26 billion and Operating EPS increased 5% to $2.30. For the first half, net sales grew 4% to $11,284 million, GAAP income from continuing operations was $1.94 billion with EPS of $2.88, and non-GAAP Operating EBITDA and Operating EPS rose to $3.70 billion and $3.80 per share, up 10% and 14%.
Seed first-half net sales increased 4% to $7.56 billion and Operating EBITDA grew 11% to $3.00 billion, supported by 3% price/mix gains. Crop Protection first-half net sales rose 3% to $3.73 billion, with Operating EBITDA up 9% to $776 million despite pricing pressure in Latin America. Cash used in operating activities from continuing operations was $3,345 million for the first half versus $1,139 million in the prior-year period.
Reflecting the strong first-half performance, the company raised full-year 2026 guidance, now expecting non-GAAP Operating EBITDA of $4.1 billion to $4.3 billion and Operating EPS of $3.60 to $3.80 per share. Corteva also reaffirmed that it remains on track to complete the planned separation and Vylor spin-off on October 1, 2026, with key regulatory and governance milestones outlined.
Corteva Inc. is advancing its planned separation into two standalone public companies and reshaping its boards accordingly. In connection with the anticipated spin-off of its seed business into Vylor Inc., directors Karen Grimes, Marcos Lutz, Charles (Chuck) Magro and Kerry Preete have agreed to resign from Corteva’s board immediately before the transaction closes, with no disagreements over operations or policies cited.
These directors are expected to join the board of Vylor, which has filed its initial Form 10 registration statement with the SEC describing its business, strategy and historical financial results. Corteva also announced the future boards: Greg Page will chair the nine-member post-separation Corteva board, while Karen Grimes will serve as independent chair of Vylor’s board, initially consisting of seven directors, with the separation targeted for the fourth quarter of 2026.
Corteva, Inc. amended a prior report to update its Crop Protection Operations Strategy Restructuring Program, a multi-year effort to streamline manufacturing and cut structural costs. Management has committed to the next phase, including the intended cessation of production at its Asturias, Spain site, subject to consultation with local works council and unions, and revised plans for exiting production in Pittsburg, California.
The Company now expects aggregate pre-tax restructuring and asset-related charges of $750 million to $815 million, an increase of $100 million to $115 million. This comprises $100 million to $125 million of severance and related benefits, $350 million to $372 million of asset-related and impairment charges, and $300 million to $318 million of exit and cessation costs, including contract terminations and decommissioning and demolition. Cash payments are anticipated to total $400 million to $443 million, and actions are expected to be substantially complete by the end of 2028. Conditions for the sale of land at the Pittsburg, California site have also been agreed, subject to due diligence.
KISSAM LUTHER C IV reported acquisition or exercise transactions in this Form 4 filing.
Corteva, Inc. reported that Luther C. Kissam IV, CEO of its Crop Protection business, received a grant of 24,138 shares of Common Stock. The award was recorded at a price of $0.00 per share, reflecting a compensation-related stock grant rather than a market purchase. Following this grant, his directly held Common Stock position increased to 25,138 shares, as shown in the filing.
Corteva, Inc. executive Luther C. Kissam IV, CEO of the Crop Protection Business, filed an initial Form 3 showing beneficial ownership of 1,000 shares of Corteva common stock held directly. The filing records his starting equity position and does not report any recent share purchases or sales.